Spain claims best hep C drug prices in Europe
This article was originally published in Scrip
Executive Summary
Spanish authorities are to cap spending on new hepatitis C treatments at €727m over three years, says the health ministry. In addition, the pricing commission has authorized the funding of three new therapies: Gilead's Harvoni (sofosbuvir plus ledipasvir) and Abbvie's Viekira (ombitasvir plus paritaprevir plus ritonavir) and Exviera (dasabuvir). However, reimbursement comes with strings attached as the Spanish health minister claims to have secured the best prices in Europe.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.